MedPath

COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients

Completed
Conditions
Depression
Covid19
Anxiety
Registration Number
NCT04689464
Lead Sponsor
Alhasan Mujtaba Al-Mudhaffer
Brief Summary

The covid-19 pandemic started to spread worldwide since December 2019. It promoted to an exaggerated psychological stress and anxiety in humans due to the intolerable symptoms higher than usual death of many infected patients. This study examines the corona related anxiety and if there is need for drug intervention to treat this anxiety.

To answer these questions, a survey made to the hospitalized patients including sex, age, educational level, Marital state, and a standardized questionnaires (GAD-7 and PHQ-9) which has been validated and shown to possess good psychometric qualities in studies of participants from multiple populations.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
450
Inclusion Criteria
  • patients with COVID19 willing to participate in the study
Exclusion Criteria
  • unwilling unable to read or interact with standardized questionnaire unconscious

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
depressionat the time of acute infection, average of 1 month

Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; \>20 severe. Minimum 0 maximum 27 points

anxietyat the time of acute infection, average of 1 month

Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; \>15 severe. Minimum 0, maximum 21 points

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

AlFayhaa Teaching hospital

🇮🇶

Basra, Iraq

© Copyright 2025. All Rights Reserved by MedPath